- Home
- MGNI vs PTGX Comparison
MGNI vs PTGX Comparison
Compare MGNI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- PTGX
- Stock Information
- Founded
- MGNI 2007
- PTGX 2006
- Country
- MGNI United States
- PTGX United States
- Employees
- MGNI N/A
- PTGX N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- PTGX Health Care
- Exchange
- MGNI Nasdaq
- PTGX Nasdaq
- Market Cap
- MGNI 1.7B
- PTGX 2.8B
- IPO Year
- MGNI N/A
- PTGX 2016
- Fundamental
- Price
- MGNI $12.94
- PTGX $47.91
- Analyst Decision
- MGNI Strong Buy
- PTGX Strong Buy
- Analyst Count
- MGNI 11
- PTGX 7
- Target Price
- MGNI $16.95
- PTGX $52.83
- AVG Volume (30 Days)
- MGNI 1.3M
- PTGX 450.1K
- Earning Date
- MGNI 11-07-2024
- PTGX 11-08-2024
- Dividend Yield
- MGNI N/A
- PTGX N/A
- EPS Growth
- MGNI N/A
- PTGX N/A
- EPS
- MGNI N/A
- PTGX 2.75
- Revenue
- MGNI $649,216,000.00
- PTGX $319,120,000.00
- Revenue This Year
- MGNI $0.26
- PTGX $400.33
- Revenue Next Year
- MGNI $10.75
- PTGX N/A
- P/E Ratio
- MGNI N/A
- PTGX $17.54
- Revenue Growth
- MGNI 7.50
- PTGX 125.73
- 52 Week Low
- MGNI $6.46
- PTGX $13.76
- 52 Week High
- MGNI $15.92
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- MGNI 54.59
- PTGX 60.40
- Support Level
- MGNI $12.35
- PTGX $45.33
- Resistance Level
- MGNI $13.11
- PTGX $48.89
- Average True Range (ATR)
- MGNI 0.42
- PTGX 1.28
- MACD
- MGNI 0.11
- PTGX 0.11
- Stochastic Oscillator
- MGNI 63.58
- PTGX 77.11
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.